Australia's Immutep hits 15-month high on positive IMP761 trial update
23/12/2025 24:44
** Shares of Australia's Immutep IMM.AX rise as much as 3.8% to A$0.415, their highest since September 13, 2024 ** Biotech firm announces positive update from IMP761 first-in-human Phase I study, a LAG-3 agonist antibody for autoimmune diseases ** Co reports dose-dependent immunosuppressive effects of IMP761 against a strong foreign antigen, maintaining a favorable safety profile ** Further updates for trial expected in H1 CY2026 - Immutep ** IMM down 12.3% YTD (Reporting by Keshav Singh Chundawat in Bengaluru) ((Keshav.singhchundawat@thomsonreuters.com))